返回 
加入收藏
疏血通注射液联合瑞舒伐他汀治疗急性心肌梗死后心绞痛的临床观察
x
请在关注微信后，向客服人员索取文件
| 篇名： | 疏血通注射液联合瑞舒伐他汀治疗急性心肌梗死后心绞痛的临床观察 |
| TITLE： | |
| 摘要： | 目的：观察疏血通注射液联合瑞舒伐他汀治疗急性心肌梗死后心绞痛的疗效和安全性。方法：回顾性收集68例急性心肌梗死后心绞痛的患者资料，按用药方案的不同分为对照组（34例）和研究组（34例）。在常规治疗的基础上，对照组患者给予瑞舒伐他汀钙片10 mg，口服，每日1次；研究组患者在对照组治疗的基础上给予疏血通注射液6 mL，加入0.9％氯化钠注射液250 mL中，静脉滴注，每日1次。两组均持续治疗14 d。观察两组患者的临床疗效，治疗前后血小板活化标志物[P选择素（CD62p）、溶酶体颗粒膜糖蛋白（CD63）、血小板激活复合物1（PAC-1）、溶血磷脂酸（LPA）]、血管内皮生长功能指标[一氧化氮（NO）、内皮素1（ET-1）、血管内皮生长因子（VEGF）]水平及不良反应发生情况。结果：研究组患者总有效率（94.12％）显著高于对照组（73.53％），差异有统计学意义（P＜0.05）。治疗后，两组患者血小板活化标志物、ET-1、VEGF水平均显著低于同组治疗前，且研究组显著低于对照组；两组患者NO水平均显著高于同组治疗前，且研究组显著高于对照组，差异均有统计学意义（P＜0.05）。两组患者不良反应发生率比较，差异无统计学意义（P＞0.05）。结论：在常规治疗的基础上，疏血通注射液联合瑞舒伐他汀治疗急性心肌梗死后心绞痛的疗效显著，可有效改善血管内皮生长功能及血小板功能，且未增加不良反应的发生。 |
| ABSTRACT： | OBJECTIVE： To observe therapeutic efficacy and safety of Shuxuetong injection combined with rosuvastatin in the treatment of angina pectoris after acute myocardial infarction. METHODS： The information of 68 patients with angina pectoris after acute myocardial infarction were collected retrospectively and divided into control group （34 cases） and study group （34 cases）. Based on routine treatment， control group was given Rosuvastatin calcium tablet 10 mg orally， once a day. Study group was additionally given Shuxuetong injection 6 mL added into 0.9％ Sodium chloride injection 250 mL intravenously， once a day， on the basis of control group. Both groups were treated for 14 days. Clinical efficacies of 2 groups were observed， and the levels of platelet activation markers （CD62p， CD63， PAC-1， LPA）， vascular endothelial growth function indexes （NO， ET-1， VEGF） were observed before and after treatment. The occurrence of ADR was observed. RESULTS： The total response rate of the study group was （94.12％） was significantly higher than that of control group （73.53％）， with statistical significance （P＜0.05）. After treatment， the levels of platelet activation markers， ET-1 and VEGF of 2 groups were significantly lower than before treatment， the study group was significantly lower than the control group； the levels of NO in 2 groups were significantly higher than before treatment， the study group was significantly higher than the control group， with statistical significance （P＜0.05）. There was no statistical significance in the incidence of ADR between 2 groups （P＞0.05）. CONCLUSIONS： Based on routine treatment， Shuxuetong injection combined with rosuvastatin show significant therapeutic efficacy for angina pectoris after acute myocardial infarction， which can effectively improve vascular endothelial growth function and platelet function， without increasing the occurrence of ADR. |
| 期刊： | 2018年第29卷第2期 |
| 作者： | 张彩霞，余晓峰，刘杰祥 |
| AUTHORS： | ZHANG Caixia，YU Xiaofeng，LIU Jiexiang |
| 关键字： | 疏血通注射液；瑞舒伐他汀；急性心肌梗死后心绞痛；疗效；安全性 |
| KEYWORDS： | Shuxuetong injection； Rosuvastatin； Angina pectoris after acute myocardial infarction； Therapeutic efficacy； Safety |
| 阅读数： | 297 次 |
| 本月下载数： | 4 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
